Ling Mo
About Ling Mo
Ling Mo is the Head of Innovative Medicine Early Development at Bristol-Myers Squibb in Shanghai, China, specializing in virology, immunoscience, and early asset development.
Current Role at Bristol-Myers Squibb
Ling Mo currently holds the position of Head of Innovative Medicine Early Development at Bristol-Myers Squibb in Shanghai City, China. He is responsible for leading the China early asset team and evaluating early asset development and strategic planning. In his role, Ling Mo focuses on guiding the development of non-oncology assets in areas such as cardiovascular, fibrosis, and immunology.
Previous Positions at Bristol-Myers Squibb
Before his current role, Ling Mo served in multiple capacities at Bristol-Myers Squibb. These included Disease Area Head Virology, Director from 2014 to 2015, and Senior Disease Area Specialist Virology, Associate Director from 2011 to 2013. He was also a Disease Area Specialist from 2007 to 2011. His responsibilities over these years contributed significantly to virology research and the management of disease area-specific projects.
Academic Background and Early Career
Ling Mo studied at Fudan University, where he earned a Ph.D. in infectious disease from 1998 to 2003, and an M.D. in clinical medicine from 1993 to 1998. He later worked as a Post Doctor at the University of California, San Diego, USA from 2005 to 2006. His early career also includes a position as an attending physician specializing in infectious diseases at Huashan Hospital Affiliated to Fudan University from 2006 to 2007.
Expertise in Drug Development and Research
Ling Mo brings extensive experience in drug development and research. At Bristol-Myers Squibb, he contributes to post-launch product life cycle management, including Phase IV trials, label updates, license renewals, publication development, and interactions with Key Opinion Leaders (KOLs). His work encompasses delivering solutions in dermatology, gastroenterology, pulmonology, and rheumatology, as well as developing cell therapies, biologics, targeted protein degradation, and antibody-drug conjugates.
Focus on Transforming Lives Through Science
Ling Mo is committed to transforming lives through science, focusing on therapeutic areas such as oncology, hematology, immunology, cardiovascular, and neuroscience. His work aims to discover and develop medicines that modify diseases and improve the quality of life. This encompasses research on novel drug delivery technologies and millamolecules, mid-range compounds that interrupt protein-protein interactions.